Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Gasparini

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Neuroscience|August 10, 2017
Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugsCatherine Lévesque, Giovanni Hernandez, Souha Mahmoudi, et al.
Expert Opinion on Investigational Drugs|November 21, 2013
Development of mavoglurant and its potential for the treatment of fragile X syndromeBaltazar Gomez-Mancilla, Elizabeth Berry-Kravis, Randi Hagerman, et al.
The Journal of Organic Chemistry|August 3, 2002
Spiro[2.2]pentane as a dissymmetric scaffold for conformationally constrained analogues of glutamic acid: focus on racemic 1-aminospiro[2.2]pentyl-1,4-dicarboxylic acidsRoberto Pellicciari, Maura Marinozzi, Emidio Camaioni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 11, 2003
In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signalingJoanna M Wierońska, Maria Smiałowska, Piotr Brański, et al.
Bioorganic & Medicinal Chemistry|October 16, 2014
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterizationIvo Vranesic, Silvio Ofner, Peter Josef Flor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 12, 2007
Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteersValerie Treyer, Johannes Streffer, Simon M Ametamey, et al.
Parkinsonism & Related Disorders|February 15, 2011
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeysLaurent Grégoire, Nicolas Morin, Bazoumana Ouattara, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 19, 2007
Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methodsValerie Treyer, Johannes Streffer, Matthias T Wyss, et al.
Psychopharmacology|November 1, 2013
The challenges of clinical trials in fragile X syndromeSébastien Jacquemont, Elizabeth Berry-Kravis, Randi Hagerman, et al.
Brain Structure & Function|June 28, 2014
Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brainBalázs Gulyás, Judit Sovago, Baltazar Gomez-Mancilla, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Neuroscience|August 10, 2017
Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugsCatherine Lévesque, Giovanni Hernandez, Souha Mahmoudi, et al.
Expert Opinion on Investigational Drugs|November 21, 2013
Development of mavoglurant and its potential for the treatment of fragile X syndromeBaltazar Gomez-Mancilla, Elizabeth Berry-Kravis, Randi Hagerman, et al.
The Journal of Organic Chemistry|August 3, 2002
Spiro[2.2]pentane as a dissymmetric scaffold for conformationally constrained analogues of glutamic acid: focus on racemic 1-aminospiro[2.2]pentyl-1,4-dicarboxylic acidsRoberto Pellicciari, Maura Marinozzi, Emidio Camaioni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 11, 2003
In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signalingJoanna M Wierońska, Maria Smiałowska, Piotr Brański, et al.
Bioorganic & Medicinal Chemistry|October 16, 2014
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterizationIvo Vranesic, Silvio Ofner, Peter Josef Flor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 12, 2007
Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteersValerie Treyer, Johannes Streffer, Simon M Ametamey, et al.
Parkinsonism & Related Disorders|February 15, 2011
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeysLaurent Grégoire, Nicolas Morin, Bazoumana Ouattara, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 19, 2007
Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methodsValerie Treyer, Johannes Streffer, Matthias T Wyss, et al.
Psychopharmacology|November 1, 2013
The challenges of clinical trials in fragile X syndromeSébastien Jacquemont, Elizabeth Berry-Kravis, Randi Hagerman, et al.
Brain Structure & Function|June 28, 2014
Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brainBalázs Gulyás, Judit Sovago, Baltazar Gomez-Mancilla, et al.
Pageof 7